← All candidates
Two insider buys in the last year — $20.2K in all.
30 filings on record.
CMMBChemomab Therapeutics Ltd.
NasdaqCM · Healthcare · $18.10M
$2.47
+0.82% · Sep 15
Two insider buys in the last year — $20.2K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 2 sells
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CMMB ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$18.10M
Float
6.1M
83% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Executive Officer
Mor George Adi
Bought $10.2K on May 29 — 4,926 sh @ $2.08, held direct, 3.5% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
28 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
1 more transaction on Pro →Context
Wall St
$15.00 avg target
+507.3% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.00 act−$0.00
Q4 '25−$0.00 act+$0.01
Q3 '25−$0.00 act+$0.04
Q2 '25−$0.02 act+$0.02
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice